Transgene Biotek

Healthcare Services

526139 BSE

BSE: 526139 Healthcare Service Provider

₹2.57

Close · 04 Nov 2026

P/E: Not meaningful: loss-making over the last twelve months

View as Markdown

MCP

Close 4 Nov 2026 ₹2.57 −0.82 −24.2% 1Y

Start ₹3.39

Key Fundamentals

MicrocapHealthcare ServicesHealthcare

Price-based figures at the 04 Nov 2026 close · EPS basis: Consolidated · TTM

ROCE: −2.36%
Debt to Equity: 2.05
EPS (TTM): −₹0.21
Book Value: ₹1.11

Market Cap: —
P/E (TTM): Not meaningful: loss-making over the last twelve months
P/B: 2.32
ROE: −17.90%
Dividend Yield: 0.00%
EBITDA: −₹54.00 L
52W High: ₹4.19
52W Low: ₹1.83

Tapetide Score

Data-driven rating, 0–100, as of 4 Nov 2026. How it works →

Overall score

36 Poor

Data confidence 91/100

Category scores

Quality: 26; Poor; Returns, margins, earnings quality 22% weight
Valuation: 45; Weak; Cheap vs sector & own history 24% weight
Growth: 14; Poor; Sales & profit trajectory 9% weight
Financial Health: 11; Poor; Solvency, leverage, coverage 9% weight
Momentum: 36; Poor; Trend strength, vol-adjusted 12% weight
Ownership: 50; Average; FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

No strengths listed

Weaknesses

Company has low interest coverage ratio.
Promoter holding is low: 23.6%
Company has a low return on equity of -9.77% over last 3 years.
Company might be capitalizing the interest cost

Technical Indicators

Technical signals: verdict and indicator counts
Group	Signal	Bearish	Neutral	Bullish
Overall	Bearish	7	6	6
Oscillators	Bullish	1	6	2
Moving Averages	Strong Bearish	6	0	4

Oscillators

Bullish

Bearish

Neutral

Bullish

Overall

Bearish

Neutral

Bullish

Moving Averages

Strong Bearish

Bearish

Neutral

Bullish

Key readings

RSI (14): 52.77; Neutral
MACD (12,26,9): −0.05; Bullish
SMA (50): 2.62; Bearish
SMA (200): 2.74; Bearish

As of 4 Nov 2026

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y	+1.55%
5Y	+4.32%
3Y	+51.83%
1Y	−19.23%
TTM	−22.22%

Net profit

Net profit growth by window
10Y	Loss narrowed by ₹19.89 Cr
5Y	Loss narrowed by ₹8.78 Cr
3Y	Loss narrowed by ₹4.36 Cr
1Y	Loss widened by ₹0.97 Cr
TTM	Loss widened by ₹0.31 Cr

Operating cash flow

Operating cash flow growth by window
10Y	Turned negative
5Y	Turned negative
3Y	Turned negative
1Y	Turned negative
TTM	—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y	+376.19 pp
5Y	+54.62 pp
3Y	Tiny sales
1Y	+173.63 pp
TTM	+83.60 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017	₹0.28 Cr
Mar 2018	₹0.12 Cr
Mar 2019	₹0.07 Cr
Mar 2020	₹0.00 Cr
Mar 2021	₹0.17 Cr
Mar 2022	₹0.09 Cr
Mar 2023	₹0.06 Cr
Mar 2024	₹0.23 Cr
Mar 2025	₹0.26 Cr
Mar 2026	₹0.21 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017	−₹19.86 Cr
Mar 2018	−₹6.44 Cr
Mar 2019	−₹8.79 Cr
Mar 2020	−₹10.96 Cr
Mar 2021	−₹10.43 Cr
Mar 2022	−₹10.40 Cr
Mar 2023	−₹6.01 Cr
Mar 2024	−₹0.66 Cr
Mar 2025	−₹0.68 Cr
Mar 2026	−₹1.65 Cr

Quarterly Results

₹ Cr

526139 quarterly results, ₹ crore
Particulars	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	0.1	0.05	0.05	0.05	0.05	0.06	0.08	0.08	0.05	0.05	0.05	0.05	0.06
Expenses	0.22	0.17	0.16	0.32	0.46	0.13	0.17	0.62	0.18	0.13	0.1	0.33	0.12
Operating Profit	−0.12	−0.12	−0.11	−0.27	−0.41	−0.07	−0.09	−0.54	−0.13	−0.08	−0.05	−0.28	−0.06
OPM %	−120%	−240%	−220%	−540%	−820%	−116.67%	−112.5%	−675%	−260%	−160%	−100%	−560%	−100%
Other Income	0.04	0.04	0.04	0.05	0.65	0.04	0.04	0.04	0	0	0	0.15	0
Interest	0.03	0.03	0.03	0.03	0.02	0.02	0.02	0.19	0.25	0.26	0.27	0.28	0.29
Depreciation	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.05	0.05	0.05	0.05	0.04
PBT	−0.13	−0.13	−0.12	−0.27	0.2	−0.07	−0.09	−0.71	−0.43	−0.39	−0.37	−0.46	−0.39
Tax %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Net Profit	−0.13	−0.13	−0.12	−0.27	0.2	−0.07	−0.09	−0.71	−0.43	−0.39	−0.37	−0.46	−0.39
EPS (₹)	−0.02	−0.02	−0.02	−0.04	0.03	−0.01	−0.01	−0.09	−0.06	−0.05	−0.05	−0.06	−0.05

Profit & Loss

₹ Cr

526139 profit and loss, annual, ₹ crore
Particulars	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	0.3	0.18	0.28	0.12	0.07	0	0.17	0.09	0.06	0.23	0.26	0.21	0.21
Expenses	1.9	1.32	2.84	2.22	0.75	0.87	0.7	0.55	0.68	0.83	1.38	0.75	0.68
Operating Profit	−1.6	−1.14	−2.56	−2.1	−0.68	−0.87	−0.53	−0.46	−0.62	−0.6	−1.12	−0.54	−0.47
OPM %	−533.33%	−633.33%	−914.29%	Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.	−971.43%	—	−311.76%	−511.11%	Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.	−260.87%	−430.77%	−257.14%	−223.81%
Other Income	0.01	0.17	0.66	7.37	2.04	0.18	0.27	0.21	0.18	0.18	0.78	0.15	0.15
Interest	0.36	0.07	0.43	1.03	0.26	0.38	0.27	0.23	0.62	0.14	0.24	1.06	1.1
Depreciation	17.18	20.5	17.53	9.89	9.89	9.9	9.91	9.92	4.95	0.09	0.09	0.2	0.19
PBT	−19.13	−21.54	−19.86	−5.65	−8.79	−10.97	−10.44	−10.4	−6.01	−0.65	−0.67	−1.65	−1.61
Tax %	0%	0%	0%	13.98%	0%	0%	0%	0%	0%	0%	0%	0%	—
Net Profit	−19.14	−21.54	−19.86	−6.44	−8.79	−10.96	−10.43	−10.4	−6.01	−0.66	−0.68	−1.65	−1.61
EPS (₹)	−2.53	−2.84	−2.62	−0.85	−1.16	−1.45	−1.38	−1.37	−0.79	−0.09	−0.09	−0.22	−0.21
Div. Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	—

Balance Sheet

₹ Cr

526139 balance sheet, annual, ₹ crore
Particulars	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	75.77	75.77	75.77	75.77	75.77	75.77	75.77	75.77	75.77	75.77	75.77	75.77
Reserves	116	98.67	−16.9	−23.34	−32.13	−43.1	−53.53	−58.39	−64.4	−65.06	−65.74	−67.39
Borrowings	14.43	15.28	16.01	9.84	9.14	10.33	11.33	12.01	13.11	14	14.52	17.14
Other Liabilities	138	123	123	124	124	124	123	118	118	118	120	118
Total Liabilities	344	313	198	187	177	167	157	147	142	142	144	144
Fixed Assets	163	141	61.16	50.97	41.1	31.2	21.32	11.4	6.45	6.36	7.96	9.63
CWIP	0.29	0.29	2.04	1.87	1.87	1.87	1.87	1.87	1.87	1.87	1.87	0
Investments	0	0	0	0	0	0	0	0.1	0.1	0.1	0.1	0.09
Other Assets	180	172	135	134	134	134	134	134	134	134	134	134
Total Assets	344	313	198	187	177	167	157	147	142	142	144	144

Cash Flow

₹ Cr

526139 cash flow, annual, ₹ crore
Particulars	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2025	Mar 2026
Operating	3.52	6.47	0.02	−0.63	−1.74	0.14	0.01	0.1	0	1.2	−0.01
Investing	−4.57	−6.47	0	3.05	1.74	0	−0.03	−0.1	−0.01	−1.7	0.15
Financing	1.03	0	0	−2.37	0	−0.2	0	0	0	0.78	−0.36
Net Cash Flow	−0.02	0	0.02	0.05	0	−0.06	−0.01	0	−0.01	0.28	−0.22
Free Cash Flow	−1.05	0	0.02	2.74	−0.01	0.14	−0.02	0.1	0	−0.5	0.14
CFO/OP	−220	−568	−1	30	256	−16	−2	−22	0	−107	2

Ratios

526139 financial ratios, annual
Particulars	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.	3,326	13.04	30.42	52.14	—	21.47	40.56	60.83	15.87	14.04	17.38
Inventory Days	—	—	—	365	365	—	122	—	156	—	—	—
Days Payable	—	—	—	5,019	3,528	—	1,460	—	1,199	—	—	—
Cash Conversion Cycle	Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.	3,326	13.04	−4,623	−3,111	—	−1,317	40.56	−982	15.87	14.04	17.38
Working Capital Days	−8,529	Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.	Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.	Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.	Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.	—	Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.	Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.	Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.	Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.	Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.	Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
ROCE %	−8.83%	−10.86%	−14.69%	−10.97%	−17.91%	−22.11%	−26.56%	−32.31%	−20.01%	−2.07%	−1.75%	−2.36%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

57 extracted metrics across FY10–FY27.

Shareholding Pattern

As of Sep 2026

Public 71.72%
Promoters 23.64%
Others 4.64%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Transgene Biotek

What does Transgene Biotek Ltd do?

Incorporated in 1990, Transgene Biotek Ltd is in the business of Research & Development

Where is Transgene Biotek Ltd (TRABI) listed?

Transgene Biotek Ltd trades under code 526139 on the BSE.

Which sector does Transgene Biotek Ltd belong to?

Transgene Biotek Ltd is classified under the Healthcare Services sector, in the Healthcare Service Provider industry.

What is the 52-week high and low of Transgene Biotek Ltd?

Over the last 52 weeks Transgene Biotek Ltd has traded between ₹1.83 and ₹4.19 as of 4 Nov 2026.

What is the Return on Equity (ROE) of Transgene Biotek Ltd?

Transgene Biotek Ltd reported a return on equity of -17.90%. Its debt-to-equity ratio is 2.05.

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/526139.md for Transgene Biotek Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Hospital & Healthcare Services stocks → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List FII and DII flows, month by month How Tapetide Scores changed, month by month Stocks mutual funds are buying, month by month

Transgene Biotek

Key Fundamentals

Overall score

Category scores

Key Insights

Weaknesses

Technical Indicators

Oscillators

Overall

Moving Averages

Key readings

Growth Rate

Revenue

Net profit

Operating cash flow

Operating margin· change in pp

Revenue by year

Net profit by year

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Insights

Shareholding Pattern

Documents

Frequently Asked Questions about Transgene Biotek

Company Information

For AI agents and developers

Explore More